MOMA-313 is under development for the treatment of solid tumors including metastatic breast cancer, metastatic pancreatic cancer, metastatic prostate cancer. It acts by targeting DNA polymerase theta.

MOMA-313 is under clinical development by Moma Therapeutics and currently in Phase I for Metastatic Pancreatic Cancer.

Zacks.com users have recently been watching Meta Platforms (META) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Amid the rapid transformation of the energy sector, the global oil trading market is seizing new digital opportunities.

Here’s how you can own fractional shares of luxury cars with Dreamcars using $DCARS tokens. Earn rental income and trade car ...

The Untapped Potential of Machine Identity Management Are you aligning your cybersecurity efforts with the contemporary needs and trends? Organizations often overlook the significance and strategic ...

A look back at the audacious, rule-breaking women of ’90s alt-rock and the forces that erased their moment of glory.

The iOS app sets the stage for greater innovation and adoption of Web3 and AI technologies, redefining how users interact ...

Agen101: A Game Changer in the World of Innovative Solutions In a world where technology and innovation are progressing at ...

It even throws in a Frontiers-style, open-world hub, which gradually unfolds as our prickly pair harnesses new platform abilities. Sonic X Shadow Generations has raced to critical acclaim in ...

The rebranding marks a momentous milestone for Latica as it builds strong partnerships with providers and life science companies to optimize the full potential of interconnected data, revolutionizing ...